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Summary. The aim of the present study was to
characterise the expression pattern of claudin-7 tight
junction protein in canine normal liver, hyperplastic and
primary neoplastic lesions of the canine liver and
whether this tight junction protein can help differentiate
canine cholangiocarcinomas from canine hepatocellular
carcinomas. Methods and results: Necropsy samples
included 15 canine normal liver tissue samples, 10
hepatocellular nodular hyperplasias, 6 hepatocellular
adenomas, 15 well-differentiated and 6 poorly
differentiated hepatocellular carcinomas, 6
cholangiocellular hyperplasias, 10 cholangiocellular
adenomas, 15 well-differentiated and 6 poorly
differentiated cholangiocarcinomas, 6 normal
extrahepatic bile ducts, 8 normal gall bladder tissue
samples, and 5 cystic mucinous hyperplasias of the gall
bladder. In all canine normal liver tissue samples the
hepatocytes were negative for claudin-7 and the normal
biliary epithelial cells showed intense basolateral
membrane claudin-7 positivity. In all cholangiocellular
hyperplasia samples and in all cholangiocellular
adenoma samples the benign cholangiocytes showed
intense basolateral membrane positivity for claudin-7. In
all samples of the well-differentiated and poorly
differentiated cholangiocarcinomas, the malignant
neoplastic biliary epithelial cells showed intense
basolateral membrane positivity for claudin-7. Neither
the hyperplastic nodules of the liver cells nor the
hepatocellular adenomas reacted with claudin-7. The
well-differentiated and poorly differentiated
hepatocellular cancers were negative for claudin-7. The
epithelial cells of canine normal extrahepatic bile ducts,
gall bladder and cystic mucinous hyperplasias of the gall
bladder showed intense basolateral membrane positivity
for claudin-7. Differences in the intensity of claudin-7
reaction were not apparent among different types of
proliferative lesions of cholangiocytes or degrees of
cellular differentiation of neoplastic biliary epithelial
cells. 
Conclusion: Consequently, we hypothesize that
claudin-7 is an excellent immunohistochemical marker
of the cholangiocellular differentiation in canines and
can be used to detect benign and malignant proliferative
lesions of the canine biliary tract. It can also help to
differentiate canine cholangiocarcinomas from
hepatocellular carcinomas. 




The most common primary malignancies of the
canine liver are canine hepatocellular carcinomas
(cHCCs) and canine cholangiocarcinomas (cCCs). The
most common question which arises in connection with
the differential diagnosis of the canine liver is whether it
is cHCC or cCC (Patnaik et al., 1981; Trigo et al., 1982).
There are several immunohistochemical markers
available which help to produce a differential diagnosis
in this oncopathological question (De las Mulas et al.,
1995; Ramos-Vara et al., 2001). 
Claudins are a relatively large family of 17-27 kDa
integral membrane tight junction tetraspanin proteins
that are classified on the basis of the size of the
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molecules which pass through the paracellular spaces
between epithelial and endothelial cells. Tight junctions
are the most apical cell-cell contacts and are important
for barrier function in epithelial and endothelial cells
(Tsukita et al., 2001; Tsukita and Furuse, 2002). The
barrier function of the tight junctions and claudins
regulates the passage of ions, water, and growth factors
through paracellular space. The tight junctions and
claudins between epithelial cells form a polarized barrier
between luminal and serosal compartments and
segregate luminal growth factor from their basal-lateral
receptors. This property may promote cancer formation
in preneoplastic, premalignant tissues in which the tight
junctions and claudins have become chronically leaky to
growth factors (Mullin, 1997). Claudin-5 molecule can
be used as a differential marker, in the differential
diagnosis of canine hemangiosarcomas from other
sarcomas (Jakab et al., 2009).
This study has investigated whether claudin-7
antibody, which is commonly used in diagnostic human
pathology (Li et al., 2004; Johnson et al., 2005; Hornsby
et al., 2007), can be demonstrated by immunohisto-
chemical methods in routinely processed tissue samples
of canine normal liver, hyperplastic and neoplastic
lesions of the canine liver and whether this tight junction
protein can help differentiate cCCs from cHCCs. To our
knowledge, this is the first study that has examined
claudin-7 molecule expression in canine normal liver
tissue and different proliferative lesions of canine
hepatocytes and cholangiocytes.
Materials and methods
Samples of canine tumours
Tissue samples were collected at Szent István
University, Faculty of Veterinary Science, Department of
Pathology and Forensic Veterinary Medicine (Budapest,
HU) between 2004 and 2009. The necropsy samples
(n=108) included 15 canine normal liver tissue samples,
10 hepatocellular nodular hyperplasias, 6 hepatocellular
adenomas, 15 well-differentiated cHCCs, 6 poorly
differentiated cHCCs and 6 cholangiocellular
hyperplasias (from cirrhotic liver), 10 cholangiocellular
adenomas, 15 well-differentiated cCCs, 6 poorly
differentiated cCCs, 6 normal extrahepatic bile ducts, 8
normal gall bladder tissue samples, and 5 cystic
mucinous hyperpalsias of the gall bladder. All samples
were collected during the necropsy of canines. In none
of the cases did we find malignant primary tumours in
the pancreas, stomach, small intestine, colorectum,
lungs, adrenal glands, mammary glands or kidney.
Samples were fixed in 8% neutral buffered formalin for
24 hours at room temperature, dehydrated in a series of
ethanol and xylene, and embedded in paraffin. The 3-
4µm thick sections were routinely stained with
hematoxylin and eosin (HE). Each neoplastic case was
classified by the pathologists (CSJ and JK).
Immunohistochemistry
Serial sections (3-4 µm) were initially dewaxed in
xylene and graded ethanol. After treatment with
appropriate antigen retrieval (Target Retrieval Soluton,
DAKO, Glostrup, Denmark, pH 6; microwave - 800W -
oven for 30 min), the sections were incubated with
primary antibody claudin-7 (rabbit polyclonal and
diluted 1 in 80, Zymed, Catalog number: 43-9100), for
60 min at room temperature. All primary antibodies
were produced by Zymed Inc., San Francisco, CA, USA.
Immunohistochemical labelling was performed using the
streptavidin-peroxidase procedure. Antigen-bound
primary antibody was detected using standard avidin-
biotin immunoperoxidase complex (DAKO, LSAB2
Kit). The chromogen substrate was 3, 3’-diamino-
benzidine tetrahydrochloride (DAB substrate-
chromogen, DAKO). Sections were counterstained with
Mayer’s hematoxylin. 
Negative controls were performed by omission of
the primary antibody and external positive controls were
canine normal colorectum for claudin-7 (Jakab et al.,
2010). The internal positive controls were the
peritumoural normal biliary epithelial cells
(cholangiocytes) for claudin-7, and internal negative
controls were the peritumoural normal hepatic cells and
portal fibroblasts.
Immunohistochemical assessment
A semiquantitative evaluation of the percentage of
positive tumour cells was used. In each case, two
independent observers (CSJ and JK) recorded the
distribution and intensity of labelling. The
immunoreactivity was assessed as follows: negative (-),
no immunostaining present; (+), <25% of cells positive;
(++), 25-50% of cells positive; (+++), 50-75% of cells
positive; (++++), 75-100% of cells positive. The
intensity of reaction for claudin-7 was graded on a scale
of 3, where 0 stood for no reaction, 1 for weak reaction,
2 for moderate reaction, and 3 for intense reaction.
Results
In all canine normal liver tissue samples the
hepatocytes, the endothelial cells of the sinuses and
portal vessels, the portal fibroblasts, and the Kupffer-
cells were negative for claudin-7. In these samples the
normal biliary epithelial cells of the bile ducts with
variable diameter showed ++++ diffuse, basolateral
membrane claudin-7 positivity (15/15; 100%). The
reactions were intense (grade 3) (Fig. 1A-C). In all
cholangiocellular hyperplasia samples (6/6; 100%) and
in all cholangiocellular adenoma samples (10/10; 100%)
the benign cholangiocytes showed ++++ diffuse,
basolateral membrane positivity for claudin-7 (Fig. 1D).
The reactions were grade 3 in all benign proliferative
lesions of the cholangiocytes. In all samples of the well-
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differentiated and poorly differentiated cCCs, the
malignant neoplastic biliary epithelial cells showed
diffuse, basolateral membrane positivity for claudin-7
(21/21; 100%) (Fig. 2A-D). The reactions were intense
in all cases of cCC. Neither the hyperplastic nodules of
the liver cells nor any of the hepatocellular adenomas
reacted with claudin-7. The well-differentiated and
poorly differentiated cHCCs were negative for claudin-7
in all samples (Fig. 3A-D). In canine normal
extrahepatic bile ducts the surface epithelial cells and the
epithelial cells of the propria glands showed ++++
diffuse, basolateral membrane positivity for claudin-7.
We investigated the claudin-7 immunohistochemical
pattern in canine normal gall bladder and in cystic
mucinous hyperplasias of the gall bladder. In all tissue
samples of the intact gall bladder and its hyperplastic
lesions the epithelial cells showed diffuse, intense
basolateral membrane positivity for claudin-7 (Fig. 4A-
D). 
Differences in the intensity of claudin-7 reaction
were not apparent among different types of proliferative
lesions of cholangiocytes or degrees of cellular
differentiation of neoplastic biliary epithelial cells. In the
case of hyperplastic and proliferative lesions of the
biliary tract the adjacent liver cells were the internal
negative controls.
Discussion
The differentiation of canine hepatocellular
carcinoma (cHCC) from canine cholangiocarcinoma
(cCC) can be difficult. 
In veterinary oncopathology, immunohistochemical
techniques have been used extensively on liver tumours.
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Fig. 1. A-C. The biliary epithelial cells of the canine normal intrahepatic bile ducts showed intense basolateral membrane positivity for claudin-7. On the
left hand side of the pictures normal, claudin-7 negative liver cells can be seen. D. The canine cholangiocellular adenomas showed intense membrane
claudin-7 positivity. IHC. A, x 100; B, D, x 200; C, x 400.
Frequently used antibodies include hepatocyte paraffin 1
(Hep Par 1) (Ramos-Vara et al., 2001), cytokeratins (CK
7) alpha-fetoprotein (AFP), and carcinoembryonic
antigen (CEA) (De las Mulas et al., 1995; Ramos-Vara et
al., 2001). 
In our present study we investigated the expression
pattern of claudin-7 in canine normal liver tissues and
primary liver tumours. We detected intense, basolateral
membrane claudin-7 expression in the intact biliary
epithelial cells of the canine normal liver tissue samples
(100%), and in the ductal proliferations from canine
cirrhotic liver (100%), and in benign and malignant
tumours of the canine cholangiocytes (100%; 100%).
None of the normal hepatocytes and the hyperplastic and
neoplastic lesions of the liver cells were recognized by
this claudin antibody. 
In veterinary oncological study the canine normal
liver cells showed consistently cytoplasmic,
disseminated, and granular positivity for Hep Par 1. The
eptithelial cells of the bile duct and the non-
hepatocellular tissues did not react with this antibody
(Ramos-Vara et al., 2001). In our present study the
canine normal hepatocytes, the endothelial cells of the
sinusoids and portal vessels, the portal fibroblasts, and
the Kupffer-cells were negative for claudin-7, but the
normal biliary epithelial cells showed intense basolateral
claudin-7 membrane positivity. It seems that Hep Par 1
and claudin-7 can help the correct identification of the
intact liver cells and biliary epithelial cells, and
furthermore they can differentiate between these cells.
Hep Par 1 showed granular and cytoplasmic
immunoreactivity in the canine hepatocellular nodular
hyperplasias and hepatocellular adenomas, but the
cholangicellular adenomas were negative for this
860
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Fig. 2. A,B. Canine cholangiocarcinomas showed intense membrane positivity for claudin-7. On the left hand side of the pictures normal, claudin-7
negative liver cells can be seen. C,D. Claudin-7 expression pattern in the canine poorly differentiated cholangiocarcinoma. IHC. A, x 100; B, C, x 200;
D, x 400.
antibody (Ramos-Vara et al., 2001). In our study the
tumor-like lesions of the canine liver cells and the
hepatocellular adenomas were negative for claudin-7,
but the cholangiocellular hyperplasias (from cirrhotic
liver), and cholangiocellular adenomas showed intense
membrane claudin-7 positivity. It means that the correct
identification of the non-neoplastic proliferations and
benign tumoural lesions of the canine liver cells and
biliary epithelial cells may be possible with the use of
these two antibodies. Earlier studies presented that
92.5% of the cHCCs showed positivity for Hep Par 1,
and this antibody did not react with neoplastic cells of
the cCCs (Ramos-Vara et al., 2001). In our study we
detected that the cHCCs did not react with claudin-7, but
all cCCs showed an intense positivity for this antibody.
Our conclusion was that claudin-7 (as a new marker of
the biliary epithelium) with Hep Par 1 should be
components of the immunohistochemical panel to
distinguish cHCC from cCC.
Previous studies described that the canine normal
biliary epithelial cells and the benign tumour cells of the
cholangiocellular adenomas showed cytoplasmic CK 7
immunoreactivity. Some normal bile ducts were strongly
CK 7 positive and others were negative. There was no
correlation between the diameter of the bile duct and
detection of CK 7 (Ramos-Vara et al., 2001). In our
present study the canine normal biliary epithelial cells
showed homogenous, strong claudin-7 membrane
positivity in all bile ducts with variable diameter. It
seems that claudin-7 protein is a better marker than CK 7
for the detection of canine normal biliary epithelial cells.
In our study in all cholangiocellular hyperplasia samples,
and in all cholangiocellular adenoma samples, the
benign cholangiocytes showed homogenous, membrane
positivity for claudin-7, like CK 7. Ramos-Vara et al.
(2001) described that 77% of the cCCs (14/18) were
positive for CK 7. 72% of the cCCs (13/18) showed
intense (grade 3) CK 7 immunoreactivity (Ramos-Vara
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Fig. 3. Canine hepatocellular carcinomas were negative for claudin-7 A. HE. B. IHC. C. HE. D. IHC. A, B, x 200; C, D, x 400.
et al., 2001). Contrarily, in our study we detected that in
all samples of the well-differentiated and poorly
differentiated cCCs, the neoplastic biliary epithelial cells
showed homogenous, intense (grade 3) basolateral,
membrane positivity for claudin-7 (21/21; 100%) and
75-100% of tumour cells were claudin-7 positive. Our
conclusion was that claudin-7 is a more sensitive
immunohistochemical marker than CK 7 for cCCs. Thus
claudin-7 with Hep Par 1 should make better
components of the immunohistochemical panel than CK
7 with Hep Par 1, to distinguish cHCC from cCC.
Well-differentiated cCCs are readily distinguished
from well-differentiated cHCCs from a histological point
of view, but the differential diagnostic challenge is the
case of poorly differentiated cHCCs versus cCCs. Poorly
differentiated cHCCs consist of solid sheets of neoplastic
hepatocytes with no apparent pattern. The hepatocellular
characteristics are difficult to recognize in poorly
differentiated cHCCs and the differential diagnosis
between undifferentiated cHCCs and undifferentiated
cCCs is more difficult than between well-differentiated
cHCCs and well-differentiated cCCs (Ponomarkov and
Mackey, 1976). We think that claudin-7, as an
immunohistochemical marker of cholangiocellular
differentiation, is available to assist in this differential
diagnosis. In this study we detected in all well-, and
poorly differentiated cHCCs negativity for claudin-7
protein, and in all well-, and poorly-differentiated cCCs
(100%) intense claudin-7 membrane immunoreactivity.
It means that this new immunohistochemical marker,
claudin-7, can help to produce the correct
hepatopathological diagnosis of canine hepatic
neoplasms. There was no adenoid form of cHCCs in our
samples. It is difficult to distinguish between adenoid
cHCCs and well-differentiated cCCs by routine
histological method, but we think that with claudin-7
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Fig. 4. A,B. The normal epithelial cells of the canine gall bladder were positive for claudin-7. C,D. Strong diffuse claudin-7 expression in canine cystic
mucinous hyperplasias of the gall bladder. IHC. A, x 200; B, D, x 400; C, x 40.
marker the detection of the cholangiocellular
characteristic is easy. To our knowledge, this is the first
study that has examined claudin-7 expression in canine
normal liver and primary liver tumours. According to a
veterinary study on rat liver, claudin-2 showed a lobular
gradient increasing firm periportal to pericentral
hepatocytes, claudin-3 was uniformly expressed,
claudin-4 was absent, and claudin-5 was only expressed
in endothelial junctions (Rahner et al., 2001).
A veterinary study described that only 1.6 % of the
well differentiated cHCCs (1/6) and all poorly
differentiated cHCCs (2/2) were positive for AFP, but all
moderately differentiated cHCCs were negative for this
marker. In this study all cCCs (2/2) were negative for
AFP. The cHHCs were negative for CEA, but CEA
positive neoplastic cells were present in all cCCs (2/2)
and in the cholangiocellular part of the mixed
carcinomas (3/3). CEA immunoreactivity was observed
within the cytoplasm of tumour cells (Martín De Las
Mulas et al., 1995). It seems to be that AFP and CEA
immunohistochemical panel can help in the
differentiation of cCCs from cHCCs, but we think that, a
higher number of investigated samples (normal biliary
epithelial cells, cholangiocellular adenomas, cCCs) are
needed to compare the sensitivity and specifity of CEA
and claudin-7 for cholangiocellular differentiation.
A human oncological study described that claudin-4
expression seems to be a useful marker in differentiating
hCCs from hHCCs and could well become a potential
diagnostic tool. In this study an intense membranous
immunolabeling was found for claudin-4 in all hCCs
unrelated to the primary site of origin, namely
intrahepatic, extrahepatic or gall bladder cancers. Intact
biliary epithelial cells showed weak positivity for
claudin-4. In contrast, normal liver cells and tumour
cells of hHCCs did not express claudin-4 (Lódi et al.,
2006). 
Another hepatopathological human study, Németh et
al. 2009, used a similar claudin-7 antibody (rabbit
polyclonal, Zymed, Catalog number: 43-9100) as we did
and a similar dilution (1:80) to ours. In this human study
the intensity of the immunoreactions was scored as none,
weak, moderate, or strong (Németh et al., 2009). We
summarised their results in comparison to our findings in
table (Table 1). It seems that claudin-7 protein is
expressed more strongly in canine normal intrahepatic
bile ducts than in human intact intrahepatic bile ducts.
Claudin-7 protein is expressed more strongly in cCCs
than in intrahepatic hCCs, and is a more useful specific
and sensitive marker in veterinary hepatopathology than
in human hepatopathology for the detection of
malignancy of the cholangiocytes. It seems that claudin-
7 protein is expressed more strongly in canine normal
extrahepatic bile ducts and normal gallbladder than in
human intact extrahepatic bile ducts and intact
gallbladder. Further morphological studies are needed to
investigate the claudin-7 expression pattern in canine
extrahepatic bile duct cancers. 
In our study we investigated claudin-7 expression in
the canine cystic mucinous hyperplasias of the gall
bladder. The histopathological hallmarks of this lesion
are the hyperplasia of the epithelium with papillary
projections and increased mucin production and the
abundance of variably sized cystic spaces that distort and
thicken the entire mucosa. The numerous 1 to 3 mm
cysts are lined with a single layer of epithelial cells. The
etiology of this lesion is unknown and may be a response
to progestational compounds (Kovatch et al., 1965;
Mawdesley-Thomas and Noel, 1967). The hyperplastic
epithelial cells in the cystic hyperplasia of the
gallbladder showed intense membrane positivity and the
percentage of claudin-7 positive hyperplastic cells was
100%. Further morphological studies are needed to
investigate the claudin-7 expression pattern in extremely
rare canine gall bladder cancers.
The results of human studies suggest that increased
expression of claudin-1 and -2 characterizes the more
differentiated foetal component in hepatoblastomas and
is a reliable marker for differentiating foetal and
embryonal types in hepatoblastomas (Halász et al.,
2006). Further studies are needed to investigate claudin-
7 expression in the rare canine hepatoblastomas and
other different primary non-hepatocellular and non-
cholangiocellular cancers, such as neuroendocrine
tumours (carcinoids). The canine liver is a common site
of tumour metastasis from mammary gland cancers,
adenocarcinoma of small intestine, exocrine part of
pancreas, stomach, colorectum, pulmonary carcinomas,
and also from cortical cancer of suprarenal gland or
phaeochromocytoma of suprarenal gland, but rarely
from renal cancers (Patnaik et al., 1981). Our aim in the
future is to investigate the expression of claudin-7 in
hepatic metastatic tumours, to find out whether this
claudin can help in the distinction of cCCs and cHCs
from metastatic neoplasms.
In summary, our results show that claudin-7 is an
excellent immunohistochemical marker of the
cholangiocellular differentiation in canines and can be
used to detect benign and malignant proliferative lesions
of the canine biliary epthelial cells. It could also be of
diagnostic value in the differential diagnosis of cCCs
from cHCCs.
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Table 1. Comparison of the results of the human and veterinary studies
on claudin-7 expression in normal and neoplastic biliary tract and
gallbladder.
Claudin-7 intensity Percentage of 
claudin-7 positive cells
1.a. Human normal cholangiocytes weak 50-74%
1.b. Canine normal cholangiocytes strong 100%
2.a. Human cholangiocarcinoma none 0-24%
2.b. Canine cholangiocarcinoma strong 75-100%
3.a. Human extrahepatic bile duct weak 25-49%
3.b. Canine extrahepatic bile duct strong 100%
4.a. Human gallbladder weak 50-74%
4.b. Canine gallbladder strong 100%
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